(Q34326845)

1 August 2017

1 reference

title

Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer (English)

1 reference

1 August 2017

1 reference

Dhingra K

1

1 reference

1 August 2017

publication date

1 January 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

19

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

649-659

1 reference

Use of tamoxifen for breast cancer: twenty-eight years later

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Is tamoxifen effective in prevention of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Coronary heart disease mortality and adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Tamoxifen-associated eye disease. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Oestrogen directly stimulates growth factor signal transduction pathways in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

The human estrogen receptor has two independent nonacidic transcriptional activation functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Identification of a third autonomous activation domain within the human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Molecular determinants of tissue selectivity in estrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Antiestrogens--tamoxifen, SERMs and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

Tamoxifen and the endometrium: findings of pelvic ultrasound examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100104293

21 January 2018

Identifiers

DOI

10.1081/CNV-100104293

1 reference

1 August 2017

1 reference